Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.56 indicates a potential upside of 175.1%.The average comprises nine short-term price targets ranging from a low of $18 to a high of $68, with a standard deviation of $15.13. While the lowest estimat ...